Literature DB >> 23175993

FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23175993

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  5 in total

1.  Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.

Authors:  Kentaro Miyake; Kei Kawaguchi; Tasuku Kiyuna; Masuyo Miyake; Kentaro Igarashi; Zhiying Zhang; Takashi Murakami; Yunfeng Li; Scott D Nelson; Irmina Elliott; Tara Russell; Arun Singh; Yukihiko Hiroshima; Masashi Momiyama; Ryusei Matsuyama; Takashi Chishima; Itaru Endo; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

Review 2.  What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.

Authors:  Enrico Bronte; Giuseppe Bronte; Giuseppina Novo; Fabrizio Bronte; Maria Grazia Bavetta; Giuseppe Lo Re; Giuseppe Brancatelli; Viviana Bazan; Clara Natoli; Salvatore Novo; Antonio Russo
Journal:  Oncotarget       Date:  2015-11-03

3.  Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.

Authors:  Zhenghu Chen; Yanling Zhao; Yang Yu; Jonathan C Pang; Sarah E Woodfield; Ling Tao; Shan Guan; Huiyuan Zhang; Shayahati Bieerkehazhi; Yan Shi; Roma Patel; Sanjeev A Vasudevan; Joanna S Yi; Jodi A Muscal; Guo-Tong Xu; Jianhua Yang
Journal:  Oncotarget       Date:  2017-10-24

4.  Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.

Authors:  Yinying Wu; Yangwei Fan; Danfeng Dong; Xuyuan Dong; Yuan Hu; Yu Shi; Jiayu Jing; Enxiao Li
Journal:  Ther Adv Med Oncol       Date:  2020-07-15       Impact factor: 8.168

5.  Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

Authors:  Estelle Daudigeos-Dubus; Ludivine Le Dret; Claudia Lanvers-Kaminsky; Olivia Bawa; Paule Opolon; Albane Vievard; Irène Villa; Mélanie Pagès; Jacques Bosq; Gilles Vassal; Dieter Zopf; Birgit Geoerger
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.